Literature DB >> 12576501

Heterologous expression of wild-type and mutant beta-cardiac myosin changes the contractile kinetics of cultured mouse myotubes.

Gaynor Miller1, Joanne Maycock, Ed White, Michelle Peckham, Sarah Calaghan.   

Abstract

The properties of myosin expressed in muscle are a major determinant of muscle performance. In this study we used a novel approach to examine the functional impact of changes in myosin heavy chain (MHC) isoform expression, as well as the consequences of expressing the mutant MHC implicated in familial hypertrophic cardiomyopathy (FHC). Cultured mouse myoblasts that normally express fast embryonic myosin were untransfected, or stably transfected with a plasmid expressing either wild-type (cWT) or mutant (D778G or G741R) beta-cardiac myosin. After differentiation for 5-7 days, cWT or mutant beta-cardiac myosin was expressed at 25 % of total myosin in the myotube. We measured time-to-peak shortening (ttp), time for half-relaxation (t0.5), the maximum velocity of shortening (Vmax) at 1 Hz stimulation, and the tetanic fusion frequency. Expression of cWT beta-cardiac myosin significantly increased ttp and t0.5 and decreased the fusion frequency compared with untransfected myotubes. However, when we compared myotubes expressing mutant beta-cardiac myosin with those expressing cWT beta-cardiac myosin, we found that ttp and t0.5 were significantly decreased, and Vmax was increased for the D778G mutant, whereas ttp, t0.5 and Vmax were unchanged for the G741R mutant. The fusion frequency was increased for both mutant myosins. Our data support the conclusion that the impact of the slower myosin isoform dominates when both slow and fast isoforms are present. This work suggests that FHC associated with either D778G or G741R mutation in MHC is an 'energy cost' disease, but that the phenotype of D778G is more severe than that of G741R.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576501      PMCID: PMC2342801          DOI: 10.1113/jphysiol.2002.031922

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  35 in total

Review 1.  Enhanced myosin function due to a point mutation causing a familial hypertrophic cardiomyopathy.

Authors:  R L Moss; J S Periera
Journal:  Circ Res       Date:  2000-04-14       Impact factor: 17.367

2.  N232S, G741R and D778G beta-cardiac myosin mutants, implicated in familial hypertrophic cardiomyopathy, do not disrupt myofibrillar organisation in cultured myotubes.

Authors:  G Miller; M Colegrave; M Peckham
Journal:  FEBS Lett       Date:  2000-12-15       Impact factor: 4.124

Review 3.  New concepts in hypertrophic cardiomyopathies, part I.

Authors:  R Roberts; U Sigwart
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

Review 4.  Myosin isoforms, muscle fiber types, and transitions.

Authors:  D Pette; R S Staron
Journal:  Microsc Res Tech       Date:  2000-09-15       Impact factor: 2.769

5.  Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis.

Authors:  E Blair; C Redwood; H Ashrafian; M Oliveira; J Broxholme; B Kerr; A Salmon; I Ostman-Smith; H Watkins
Journal:  Hum Mol Genet       Date:  2001-05-15       Impact factor: 6.150

6.  R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level.

Authors:  K A Palmiter; M J Tyska; J R Haeberle; N R Alpert; L Fananapazir; D M Warshaw
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

7.  Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects.

Authors:  J C Tardiff; T E Hewett; S M Factor; K L Vikstrom; J Robbins; L A Leinwand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-02       Impact factor: 4.733

8.  Investigation of a truncated cardiac troponin T that causes familial hypertrophic cardiomyopathy: Ca(2+) regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein.

Authors:  C Redwood; K Lohmann; W Bing; G M Esposito; K Elliott; H Abdulrazzak; A Knott; I Purcell; S Marston; H Watkins
Journal:  Circ Res       Date:  2000-06-09       Impact factor: 17.367

9.  Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy.

Authors:  H Yamashita; M J Tyska; D M Warshaw; S Lowey; K M Trybus
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

10.  Evidence for differential post-translational modifications of slow myosin heavy chain during murine skeletal muscle development.

Authors:  A M Maggs; P Taylor-Harris; M Peckham; S M Hughes
Journal:  J Muscle Res Cell Motil       Date:  2000-02       Impact factor: 2.698

View more
  9 in total

Review 1.  Mechanical and energetic consequences of HCM-causing mutations.

Authors:  Cecilia Ferrantini; Alexandra Belus; Nicoletta Piroddi; Beatrice Scellini; Chiara Tesi; Corrado Poggesi
Journal:  J Cardiovasc Transl Res       Date:  2009-10-09       Impact factor: 4.132

Review 2.  Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor.

Authors:  Jeffrey R Moore; Leslie Leinwand; David M Warshaw
Journal:  Circ Res       Date:  2012-07-20       Impact factor: 17.367

3.  Cardiomyopathy mutations in the tail of β-cardiac myosin modify the coiled-coil structure and affect integration into thick filaments in muscle sarcomeres in adult cardiomyocytes.

Authors:  Marcin Wolny; Melanie Colegrave; Lucy Colman; Ed White; Peter J Knight; Michelle Peckham
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

Review 4.  Targets for therapy in sarcomeric cardiomyopathies.

Authors:  Jil C Tardiff; Lucie Carrier; Donald M Bers; Corrado Poggesi; Cecilia Ferrantini; Raffaele Coppini; Lars S Maier; Houman Ashrafian; Sabine Huke; Jolanda van der Velden
Journal:  Cardiovasc Res       Date:  2015-01-29       Impact factor: 10.787

Review 5.  Poorly understood aspects of striated muscle contraction.

Authors:  Alf Månsson; Dilson Rassier; Georgios Tsiavaliaris
Journal:  Biomed Res Int       Date:  2015-04-16       Impact factor: 3.411

6.  Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy.

Authors:  Masataka Kawana; Saswata S Sarkar; Shirley Sutton; Kathleen M Ruppel; James A Spudich
Journal:  Sci Adv       Date:  2017-02-10       Impact factor: 14.136

7.  A1603P and K1617del, Mutations in β-Cardiac Myosin Heavy Chain that Cause Laing Early-Onset Distal Myopathy, Affect Secondary Structure and Filament Formation In Vitro and In Vivo.

Authors:  Francine Parker; Matthew Batchelor; Marcin Wolny; Ruth Hughes; Peter J Knight; Michelle Peckham
Journal:  J Mol Biol       Date:  2018-04-14       Impact factor: 5.469

Review 8.  Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation?

Authors:  Corrado Poggesi; Carolyn Y Ho
Journal:  J Muscle Res Cell Motil       Date:  2014-02-04       Impact factor: 2.698

9.  The R403Q myosin mutation implicated in familial hypertrophic cardiomyopathy causes disorder at the actomyosin interface.

Authors:  Niels Volkmann; Hongjun Lui; Larnele Hazelwood; Kathleen M Trybus; Susan Lowey; Dorit Hanein
Journal:  PLoS One       Date:  2007-11-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.